Cargando…
Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ophthalmic Research Center
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074473/ https://www.ncbi.nlm.nih.gov/pubmed/24982731 |
_version_ | 1782323221373124608 |
---|---|
author | Nourinia, Ramin Ahmadieh, Hamid Rezaei-Kanavi, Mozhgan Shoeibi, Nasser Kamrava, Kiana Karimi, Saeed |
author_facet | Nourinia, Ramin Ahmadieh, Hamid Rezaei-Kanavi, Mozhgan Shoeibi, Nasser Kamrava, Kiana Karimi, Saeed |
author_sort | Nourinia, Ramin |
collection | PubMed |
description | PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after the injections, all eyes were evaluated for intraocular inflammation. Electroretinography (ERG) was performed before, and one week and one month after the injections. All eyes were enucleated one month after the injection for histologic examination. RESULTS: No significant inflammatory response was observed in any eye. No significant decrease in ERG amplitude (a & b waves) was observed one week and one month after intravitreal ZA injection, as compared to baseline, BSS-treated eyes or non-injected fellow eyes. Histologic examination of the retinal pigment epithelium and neurosensory retina were unremarkable in all groups. Additionally, no significant increase in immune reactivity for glial fibrillary acidic protein was noted in any eye. CONCLUSION: Based on clinical, histopathologic and ERG findings in this experimental study, up to 8 mcg of intravitreal zoledronic acid seems to be safe in the rat eye. |
format | Online Article Text |
id | pubmed-4074473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Ophthalmic Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-40744732014-06-30 Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model Nourinia, Ramin Ahmadieh, Hamid Rezaei-Kanavi, Mozhgan Shoeibi, Nasser Kamrava, Kiana Karimi, Saeed J Ophthalmic Vis Res Original Article PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after the injections, all eyes were evaluated for intraocular inflammation. Electroretinography (ERG) was performed before, and one week and one month after the injections. All eyes were enucleated one month after the injection for histologic examination. RESULTS: No significant inflammatory response was observed in any eye. No significant decrease in ERG amplitude (a & b waves) was observed one week and one month after intravitreal ZA injection, as compared to baseline, BSS-treated eyes or non-injected fellow eyes. Histologic examination of the retinal pigment epithelium and neurosensory retina were unremarkable in all groups. Additionally, no significant increase in immune reactivity for glial fibrillary acidic protein was noted in any eye. CONCLUSION: Based on clinical, histopathologic and ERG findings in this experimental study, up to 8 mcg of intravitreal zoledronic acid seems to be safe in the rat eye. Ophthalmic Research Center 2014-01 /pmc/articles/PMC4074473/ /pubmed/24982731 Text en © 2014 Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Nourinia, Ramin Ahmadieh, Hamid Rezaei-Kanavi, Mozhgan Shoeibi, Nasser Kamrava, Kiana Karimi, Saeed Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title | Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title_full | Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title_fullStr | Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title_full_unstemmed | Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title_short | Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model |
title_sort | safety of intravitreal zoledronic acid, an anti-angiogenic bisphosphonate, in a rat model |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074473/ https://www.ncbi.nlm.nih.gov/pubmed/24982731 |
work_keys_str_mv | AT nouriniaramin safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel AT ahmadiehhamid safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel AT rezaeikanavimozhgan safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel AT shoeibinasser safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel AT kamravakiana safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel AT karimisaeed safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel |